Literature DB >> 17716638

Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat.

K A Connelly1, D J Kelly, Y Zhang, D L Prior, J Martin, A J Cox, K Thai, M P Feneley, J Tsoporis, K E White, H Krum, R E Gilbert.   

Abstract

OBJECTIVE: Diabetic cardiomyopathy is an increasingly recognized cause of cardiac failure despite preserved left ventricular systolic function. Given the over-expression of angiotensin II in human diabetic cardiomyopathy, we hypothesized that combining hyperglycaemia with an enhanced tissue renin-angiotensin system would lead to the development of diastolic dysfunction with adverse remodeling in a rodent model.
METHODS: Homozygous (mRen-2)27 rats and non-transgenic Sprague Dawley (SD) rats were randomized to receive streptozotocin (diabetic) or vehicle (non-diabetic) and followed for 6 weeks. Prior to tissue collection, animals underwent pressure-volume loop acquisition.
RESULTS: Diabetic Ren-2 rats developed impairment of both active and passive phases of diastole, accompanied by reductions in SERCA-2a ATPase and phospholamban along with activation of the fetal gene program. Structural features of diabetic cardiomyopathy in the Ren-2 rat included interstitial fibrosis, cardiac myocyte hypertrophy and apoptosis in conjunction with increased activity of transforming growth factor-beta (p<0.01 compared with non-diabetic Ren-2 rats for all parameters). No significant functional or structural derangements were observed in non-transgenic, SD diabetic rats.
CONCLUSION: These findings indicate that the combination of enhanced tissue renin-angiotensin system and hyperglycaemia lead to the development of diabetic cardiomyopathy. Fibrosis, and myocyte hypertrophy, a prominent feature of this model, may be a consequence of activation of the pro-sclerotic cytokine, transforming growth factor-beta, by the diabetic state.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716638     DOI: 10.1016/j.cardiores.2007.06.022

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  32 in total

1.  Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism.

Authors:  Darren A Yuen; Kim A Connelly; Andrew Advani; Christine Liao; Michael A Kuliszewski; Judy Trogadis; Kerri Thai; Suzanne L Advani; Yuan Zhang; Darren J Kelly; Howard Leong-Poi; Armand Keating; Philip A Marsden; Duncan J Stewart; Richard E Gilbert
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

Review 2.  Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease.

Authors:  Alexander T Mikhailov; Mario Torrado
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

3.  Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation.

Authors:  Antoinette Bugyei-Twum; Christopher Ford; Robert Civitarese; Jessica Seegobin; Suzanne L Advani; Jean-Francois Desjardins; Golam Kabir; Yanling Zhang; Melissa Mitchell; Jennifer Switzer; Kerri Thai; Vanessa Shen; Armin Abadeh; Krishna K Singh; Filio Billia; Andrew Advani; Richard E Gilbert; Kim A Connelly
Journal:  Cardiovasc Res       Date:  2018-10-01       Impact factor: 10.787

Review 4.  Basic Mechanisms of Diabetic Heart Disease.

Authors:  Rebecca H Ritchie; E Dale Abel
Journal:  Circ Res       Date:  2020-05-21       Impact factor: 17.367

Review 5.  Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy.

Authors:  Mark T Waddingham; Amanda J Edgley; Hirotsugu Tsuchimochi; Darren J Kelly; Mikiyasu Shirai; James T Pearson
Journal:  World J Diabetes       Date:  2015-07-10

6.  Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.

Authors:  James T Thackeray; Stefan Pietzsch; Britta Stapel; Melanie Ricke-Hoch; Chun-Wei Lee; Jens P Bankstahl; Michaela Scherr; Jörg Heineke; Gesine Scharf; Arash Haghikia; Frank M Bengel; Denise Hilfiker-Kleiner
Journal:  JCI Insight       Date:  2017-05-18

Review 7.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart.

Authors:  James T Thackeray; Robert A deKemp; Rob S Beanlands; Jean N DaSilva
Journal:  J Nucl Cardiol       Date:  2014-06-03       Impact factor: 5.952

9.  Comparison between myocardial infarction and diabetes mellitus damage caused angiogenesis or energy metabolism.

Authors:  Chao Li; Chengzhi Lu; Xiangdong Zhao; Xin Chen
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 10.  Diabetic cardiomyopathy.

Authors:  Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.